Related Experiment Video
Updated: Apr 14, 2026
05:49
Use of Magnetic Resonance Imaging and Biopsy Data to Guide Sampling Procedures for Prostate Cancer Biobanking
Published on: October 10, 2019
7.1K
Prostate Cancer Volume Estimation by Combining Magnetic Resonance Imaging and Targeted Biopsy Proven Cancer Core
Toru Matsugasumi1, Eduard Baco2, Suzanne Palmer3
1USC Institute of Urology, Keck School of Medicine, University of Southern California, Los Angeles, California; Department of Urology, Kyoto Prefectural University of Medicine, Kyoto, Japan.
The Journal of Urology
|April 28, 2015
Summary
A new method combining MRI and ultrasound fusion biopsy improves prostate cancer volume estimation. This approach offers more accurate predictions than traditional MRI alone, especially for smaller tumors.
Area of Science:
- Urology
- Radiology
- Oncology
Background:
- Multiparametric magnetic resonance imaging (mpMRI) can inaccurately estimate prostate cancer volume.
- Accurate cancer volume is crucial for treatment planning and prognosis.
Purpose of the Study:
- To develop and validate a novel method for estimating prostate cancer volume.
- To improve the accuracy of prostate cancer volume assessment using magnetic resonance/ultrasound (MR/US) fusion and biopsy data.
Main Methods:
- Retrospective analysis of 81 patients with localized prostate cancer undergoing radical prostatectomy.
- Development of a modified formula using MR/US fusion biopsy proven cancer core length to estimate lesion dimensions.
- Comparison of pathological cancer volume with MRI-estimated volume and the modified volume using Bland-Altman analysis.
Main Results:
- MR/US fusion biopsy core length was a stronger predictor of pathological cancer anteroposterior dimension than MRI alone (r=0.824 vs 0.607).
- The modified formula showed improved correlation with pathological cancer volume (r=0.824) compared to MRI-estimated volume (r=0.724).
- Agreement between modified volume and pathological volume was superior to MRI-estimated volume, particularly for lesions ≤ 2 ml.
Conclusions:
- Combining MRI-estimated volume with MR/US fusion biopsy core length enhances prostate cancer volume predictability.
- This novel method offers a more accurate assessment of prostate cancer volume.
- Improved volume estimation can aid in refining treatment strategies for prostate cancer.
